How US-UK drug deal will benefit patients | Letters. Many new medicines have reached NHS patients as a result of the government’s reformed pricing arrangements, writes Richard Torbett.
A apuração publicada por www.theguardian.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Many new medicines have reached NHS patients as a result of the government’s reformed pricing arrangements, writes Richard Torbett. Plus a letter from Nick HoileThe suggestion that the US-UK pharmaceutical agreement will result in excess deaths is alarmist and relies on a heavily critiqued approach to modelling how much the NHS can spend to generate health (US-UK drug deal could result in 229,000 excess deaths in England, analysis suggests, 1 July).
- Ponto de atenção: drug.
- Ponto de atenção: deal.
- Ponto de atenção: will.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Beleza.